Novavax’s Shot Is 80 Percent Effective Against COVID-19 in Adolescent Study
Novavax’s two-dose NVX-CoV2373 vaccine was nearly 80 percent effective at preventing COVID-19 infection in 12- to 17-years old in a late-stage study.
In the phase 3 trial, which enrolled 2,247 adolescents across 73 U.S. sites, neutralizing antibody responses were noninferior to those of young adults aged 18 to 26 during the period of May 2021 until September 2021, when the Delta variant was the dominant COVID-19 strain in the U.S.
Novavax said it will seek global authorizations supporting adolescent use during the first quarter of this year. The company filed for FDA Emergency Use Authorization of NVX-CoV2373 in adults late last month.